The US Food and Drug Administration (FDA) has endorsed the usage of a weight-loss drug described as a ‘game-changer’ by researchers.
Semaglutide has been used as an anti-diabetic remedy for a few years however analysis has proven it will also be used as an appetite-suppressant.
A research printed final yr seemed on the results of the drug on 2,000 overweight adults from 16 totally different nations. Long-term remedy with semaglutide led to an nearly 15 per cent weight reduction on common.
In truth, over 30 per cent of the group dropping in extra of 20 p.c of their physique weight.
‘No different drug has come near producing this stage of weight reduction – this actually is a game-changer,’ weight problems researcher Rachel Batterham from University College London, mentioned on the time.
‘For the primary time, individuals can obtain by medication what was solely attainable by weight-loss surgical procedure.’
In a news release this week, the FDA mentioned it might approve the usage of Wegovy, a semaglutide drug made by Danish pharmaceutical firm Novo Nordisk, for continual weight administration.
The remedy consists of a 2.4mg once-weekly injection for adults who’re overweight or obese with at the very least one weight-related situation, reminiscent of type-2 diabetes.
Tackling the weight problems disaster is turning into a extra urgent subject because the FDA famous that roughly 70% of Americans aged 20 or over are obese or overweight.
‘Today’s approval gives adults with weight problems or obese a useful new remedy possibility to include right into a weight administration program,’ mentioned John Sharretts, M.D., deputy director of the Division of Diabetes, Lipid Disorders, and Obesity within the FDA’s Center for Drug Evaluation and Research.
‘FDA stays dedicated to facilitating the event and approval of further secure and efficient therapies for adults with weight problems or obese.’
Here within the UK the drug from Novo Nordisk (recognized by the totally different identify Ozempic) has been obtainable as a prescription for these with diabetes since 2019.
Since the US has no nationwide well being service, will probably be as much as a person’s medical insurance to cowl the remedy. There’s no phrase on what it would value these with out insurance coverage, however in line with Forbes it may value $1,300 (£920) a month.
MORE : Overweight people could be paid to exercise in new scheme to fight obesity
MORE : Obesity-fighting drug could cut body weight by 20%
